Search
China Biopharmaceutical: Marketing Approval Granted for Recombinant Human Coagulation Factor VIIa N01 for Injection
1 day ago /
Read about 0 minute
Author：小编
China Biopharmaceutical Group's Recombinant Human Coagulation Factor VIIa N01 for Injection, trademarked as Anqixin, has received marketing approval from the National Medical Products Administration. This approval makes Anqixin the first domestically approved biological product of its kind in China, specifically designed for the treatment of bleeding in patients aged 12 and above who suffer from congenital hemophilia. Through rigorous Phase III clinical trials, Anqixin's efficacy and safety have been thoroughly established, offering patients a more cost-effective and high-quality treatment alternative.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
